文献速递外周动脉疾病

紫杉醇涂层器械治疗慢性肢体威胁性缺血后的死亡率:随机对照试验的系统评价与荟萃分析

Mortality After Paclitaxel-Coated Device Use in Patients With Chronic Limb-Threatening Ischemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
PubMed 文献 · J Endovasc Ther · 2020-02-18

该系统评价与荟萃分析检索多个数据库,纳入11项随机对照试验、共1450例外周动脉疾病患者(其中94.3%为慢性肢体威胁性缺血,CLTI),比较紫杉醇涂层器械与未涂层对照的全因死亡率。平均随访25.6个月,涂层组死亡161例(18.6%),对照组死亡116例(19.9%),RR 0.93(95%CI 0.78~1.12,p=0.45),未见短期至中期死亡率差异。

要点

  • 在以CLTI为主的人群中,紫杉醇涂层器械与未涂层对照的全因死亡率无显著差异(RR 0.93,95%CI 0.78~1.12)。
  • 汇总分析的随访以短期至中期为主,平均25.6个月,11项研究中10项随访至少12个月。
  • 该结果为荟萃分析结论,不能替代对个体患者长期风险的评估。

核心结论

  • 在以CLTI为主的外周动脉疾病患者中,紫杉醇涂层球囊或支架与未涂层对照相比,短期至中期全因死亡率未见差异。

研究设计与样本

  • 系统评价与荟萃分析,检索PubMed、Embase、Cochrane、CINAHL、DARE和PROSPERO数据库,检索日期为2019年11月5日。
  • 纳入11项随机对照试验,共1450例患者,其中紫杉醇涂层器械组866例、未涂层对照组584例;1367例(94.3%)为CLTI。
  • 单项终点为全因死亡率,采用DerSimonian and Laird随机效应模型合并,结果以相对危险度(RR)及95%CI表示。

主要发现

  • 平均随访25.6个月(范围6~60个月),11项研究中10项报告至少12个月随访。
  • 涂层组866例中死亡161例(18.6%),对照组584例中死亡116例(19.9%)。
  • 合并RR 0.93(95%CI 0.78~1.12,p=0.45)。

临床怎么用

  • 对于以CLTI为主、接受紫杉醇涂层球囊或支架治疗的患者,该荟萃分析未显示短期至中期全因死亡风险增加。
  • 临床决策仍需结合个体患者情况和随访数据综合判断。

局限性

  • 原文摘要未系统列出纳入研究的偏倚风险、异质性及随访时间差异等局限,此处不作推断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the risk of all-cause mortality after treatment with paclitaxel-coated devices vs uncoated controls in patients with chronic limb-threatening ischemia (CLTI). MATERIALS AND METHODS: A search of the PubMed, Embase, Cochrane, CINAHL, DARE, and PROSPERO databases was made on 5 November 2019 to identify randomized controlled trials (RCT) using intention-to-treat analysis to compare a paclitaxel-coated device to an uncoated device in PAD patients having clinical follow-up of at least 6 months. Half of the study population had to have CLTI or extractable data on the CLTI subgroup if <50%. The search identified 11 trials having 1450 patients randomized to a paclitaxel-coated device (n=866) or an uncoated control (n=584). There were 1367 (94.3%) patients with CLTI (range 10-429). The single endpoint was all-cause mortality, which was analyzed by pooling the mortality data in a DerSimonian and Laird random effects model. Summary statistics are expressed as relative risk ratios (RR) with a 95% confidence interval (CI). RESULTS: The mean follow-up was 25.6 months (range 6-60); 10 of 11 studies reported a minimum 12-month follow-up. There were 161 (18.6%) deaths among 866 subjects in the paclitaxel device group and 116 deaths among 584 (19.9%) subjects in the non-coated control group (RR 0.93, 95% CI 0.78 to 1.12, p=0.45). CONCLUSION: There was no observed difference in short- to midterm mortality among a pooled patient population of predominately CLTI patients treated with paclitaxel-coated balloons or stents compared with uncoated controls.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Dinh K, Gomes ML, Thomas SD, et al. Mortality After Paclitaxel-Coated Device Use in Patients With Chronic Limb-Threatening Ischemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Endovasc Ther. 2020. PMID: 32066315. doi:10.1177/1526602820904783

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。